Cytokinetics
CYTK
441 hedge funds and large institutions have $9.63B invested in Cytokinetics in 2026 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 176 increasing their positions, 135 reducing their positions, and 64 closing their positions.
158% more call options, than puts
Call options by funds: $551M | Put options by funds: $214M
30% more repeat investments, than reductions
Existing positions increased: 176 | Existing positions reduced: 135
25% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 64
9% more capital invested
Capital invested by funds: $8.87B → $9.63B (+$764M)
7% more funds holding in top 10
Funds holding in top 10: 15 → 16 (+1)
5.43% more ownership
Funds ownership: 114.13% → 119.56% (+5.4%)
2% more funds holding
Funds holding: 431 → 441 (+10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$212M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$94.1M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$69.1M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$63.1M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$60.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$132M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$125M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$48.4M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$41.2M |
| 5 |
JP Morgan Chase
New York
|
-$32.3M |
CYTK Hedge Fund Activity: Q1 2026 in Review
441 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2026, worth a combined $9.63B — up 8.6% from $8.87B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new CYTK positions and 64 closed out — a net gain of 16 holders — while 176 added to existing stakes and 135 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $212M. The largest seller was Fidelity Investments, cutting an estimated $132M.
- 441 institutional investors held Cytokinetics (CYTK) as of Q1 2026, up from 431 in Q4 2025.
- Funds reported $9.63B of Cytokinetics stock for Q1 2026, up 8.6% quarter-over-quarter.
- 80 funds opened new Cytokinetics positions in Q1 2026 and 64 closed out, a net change of +16 holders.
- The largest Cytokinetics buyer in Q1 2026 was Avoro Capital Advisors, an estimated $212M added.
- The largest Cytokinetics seller in Q1 2026 was Fidelity Investments, an estimated $132M sold.
Based on aggregated 13F filings for Q1 2026.